| Literature DB >> 32485831 |
Jayant Patwa1, Swaran Jeet Singh Flora1.
Abstract
Heavy metals are considered a continuous threat to humanity, as they cannot be eradicated. Prolonged exposure to heavy metals/metalloids in humans has been associated with several health risks, including neurodegeneration, vascular dysfunction, metabolic disorders, cancer, etc. Small blood vessels are highly vulnerable to heavy metals as they are directly exposed to the blood circulatory system, which has comparatively higher concentration of heavy metals than other organs. Cerebral small vessel disease (CSVD) is an umbrella term used to describe various pathological processes that affect the cerebral small blood vessels and is accepted as a primary contributor in associated disorders, such as dementia, cognitive disabilities, mood disorder, and ischemic, as well as a hemorrhagic stroke. In this review, we discuss the possible implication of heavy metals/metalloid exposure in CSVD and its associated disorders based on in-vitro, preclinical, and clinical evidences. We briefly discuss the CSVD, prevalence, epidemiology, and risk factors for development such as genetic, traditional, and environmental factors. Toxic effects of specific heavy metal/metalloid intoxication (As, Cd, Pb, Hg, and Cu) in the small vessel associated endothelium and vascular dysfunction too have been reviewed. An attempt has been made to highlight the possible molecular mechanism involved in the pathophysiology, such as oxidative stress, inflammatory pathway, matrix metalloproteinases (MMPs) expression, and amyloid angiopathy in the CSVD and related disorders. Finally, we discussed the role of cellular antioxidant defense enzymes to neutralize the toxic effect, and also highlighted the potential reversal strategies to combat heavy metal-induced vascular changes. In conclusion, heavy metals in small vessels are strongly associated with the development as well as the progression of CSVD. Chelation therapy may be an effective strategy to reduce the toxic metal load and the associated complications.Entities:
Keywords: ROS; endothelial dysfunction; heavy metals; oxidative stress; small vessel diseases
Mesh:
Substances:
Year: 2020 PMID: 32485831 PMCID: PMC7313017 DOI: 10.3390/ijms21113862
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic diagram of risk factors interacts to influence the development and progression of cerebral small vessel disease (CSVD).
Experimental evidences showing the role of Pb in microvascular endothelial and blood–brain barrier (BBB) dysfunctions.
| System | Concentration | Exposure Duration | Toxicity | Ref. |
|---|---|---|---|---|
| In-vitro | 25–200 µM | 48 h |
Abnormalities in hCMEC/D3 cells monolayer via an oxidative stress-mediated pathway. Oxidative stress key contributing mechanism for BBB dysfunction. | [ |
| In-vivo | 200 mg/L | 3 Months |
Blood – brain dysfunction. Endothelial cells exhibit higher pinocytotic activity and also opening of inter-endothelial tight junctions. | [ |
| In-vitro | 10−5 M and 10−6 M | 2 h, 4 h, 8 h, 16 h, and 24 h |
Reduces occludin, claudin 5, ZO1, and ZO2 protein expression. Increases the permeability of the neurotoxicant from BBB. Decreases the protein expressions that maintain the tight junction. | [ |
| In-vitro | 5 and 10 μM | Pre and post exposure |
Decreased occludin protein leading to BBB dysfunction. | [ |
| In-vivo | 4% lead carbonate | 5, 10, 15 days |
Vasogenic edema formation through the Flk1–dependent pathway. Microvascular hemorrhage development and BBB permeability to albumin. Encephalopathy by VEGF-independent pathway. | [ |
| In-vivo | 100, 200, 300 PPM/mL | eight weeks |
Disruption of BBB due to lower expression of occludin protein that might be caused by GRP78 expressions leading to Src activation and altering occluding expression. | [ |
| In-vivo | 50 mg/kg Pb acetate i.p., injection | 24 h |
Increased Aβ levels in the BCP due to abnormal Aβ homeostasis at the CP mediated by LRP1 via PKC-δ pathway. | [ |
| Primary culture | 1 μM lead | 0–60 min |
Microvessel toxicity by affecting protein kinase C activity that possible underlying mechanism Pb induced immature brain microvessels. | [ |
| In vitro | 2.5, 5, 10 μM | 6, 12, 24, 48 h |
Increased MMP-2 and MMP-9 suggesting BBB dysfunction. Reduced expressions of ZO-1 and occludin. | [ |
| In- vivo | 342 μg Pb/mL as Pb acetate | Once every other day 6 weeks |
Pb accumulation causes BBB dysfunction. Decreased expression of occluding. | [ |
Abbreviations: hCMEC/D3: Human Cerebral Microvascular Endothelial Cell Line, BBB: Blood brain barrier, Pb: Lead, RBE4: Rat Brain Endothelial 4, Flk1: Fetal Liver Kinase 1, VEGF: Vascular Endothelial Growth Factor, GRP78: Glucose Regulated Protein 78, LRP1: Low-density lipoprotein receptor-related protein-1, PKC-δ: Protein kinase C delta, MMP: Matrix metallopeptidase, ZO: Zona Occludens, BCP: Bilateral Cerebral Plexus, CP: Choroid Plexus.
Experimental evidences showing the Cu role in microvascular endothelial and BBB dysfunctions.
| System | Concentration | Exposure Duration | Toxicity | Ref. |
|---|---|---|---|---|
| In-vitro | 1.5–50 μg/mL | 0–8 h |
Cytotoxic at the higher concentration. Increase TNF-a, IL-1b and IL-2 time-dependently. | [ |
| Primary culture | 30–300 μM | 12 h |
Cu at 30–120 μM increased cell viability due to increased antioxidant activity in the cell such as CAT and SOD. Cu at 180–300 μM showed a cytotoxic effect and oxidative stress. Alter the claudin protein expression. | [ |
| In-vitro | 10 to 50 μM | 12 h |
Cu exposure increases inflammatory responses driven by the NF-κB a PI3-kinase/Akt pathway. Higher IL-8 expression. | [ |
| In-vivo | IP 50 mg/kg | 24 h |
Cu nanoparticles-induced BBB disruption. Brain edema formation. | [ |
| AD patients | - | - |
Cu was found to be deposited in the arteriolar tree in CAA. Vascular fragility observed. | [ |
| In-vivo | 1 mg/L | 4 weeks |
BBB disruption and, cerebral bleedings. Cognitive dysfunctions and anxiety observed in mice. | [ |
| In-vivo | 250 ppm | 3 or 9 months |
Cu exposure displayed AD pathology through amyloid and tau mediated pathway. | [ |
| In-vivo | 10 µg/mL | 1 h |
Acute Cu exposure decrease the vascular functions. Oxidative stress generation through the iNOS pathway. | [ |
| In- vitro | 0–500 μg/mL | 12 h |
Cu increases ROS generation and autophagy by an AMPK pathway. Cu2O crystals elicit endothelial cell death through autophagy. | [ |
| In- vitro | 100 μM | 0–16 h |
Cu increased VCAM-1, ICAM-1, and MCP-1 expression. Activate NF-κB and AP-1 signaling. | [ |
Abbreviations: BMECs: Brain microvascular endothelial cells, Cu: Copper, TNF: Tumor necrosis factor, IL: Interleukin, SPF: Specific-pathogen-free, Cucl2: Copper(II) chloride, CAT: Catalase, SOD: Super oxide dismutase, HUVEC: Human umbilical vein endothelial cell, HMEC: Human man mammary epithelial cells, HIAEC: Human lilac endothelial cells, NF-κB: Nuclear factor kappa B, PI3:Phosphoinositide 3-kinase, Akt: Protein kinase B, AD: Alzheimer’s disease, iNOS: Inducible nitric oxide synthase, CAA: Cerebral amyloid angiopathy, VCAM: Vascular cell adhesion protein, ICAM: Intercellular Adhesion Molecule, MCP: Monocyte chemo attractant protein, AP: Activator protein, ROS: Reactive Oxygen Species, AMPK: 5’ Adenosine monophosphate-activated protein kinase.
Experimental evidences showing the role of Hg in the microvascular endothelial and BBB dysfunctions.
| System | Concentration | Exposure Duration | Toxicity | Ref. |
|---|---|---|---|---|
| In-vivo | HgCl2 | 30 days |
Elevates ROS generation that causes vascular reactivity and decreases the NO bioavailability. | [ |
| In-vitro | (1.0–5.0 microM) | 24 h |
Dose-dependent cytotoxic effect on the HUVECs cell. Disruption of endothelial functions. | [ |
| In-vitro | (1, 2, 3 µM MeHg) | 24 h |
Increased LDH leakage from the cells. Reduced proliferation of endothelial cells. | [ |
| In-vivo | 20-ppm | 4 weeks |
BBB damage through the upregulation of VEGF expression. | [ |
| In-vivo | 1.0 mg/kg | 30 min, 1 h, 6 h, 12 h, 24 h, |
Endothelial and glial impairment. BBB dysfunction. | [ |
| In-vitro | (1, 2, 3, and 5 µM) | 24 h |
Increased release of PGI2 and Cox-2 from the endothelial cells and pericytes. Modulate the p38 and MAPK pathways. | [ |
| In- vitro | 1 μM | 1, 3 or 6 h, 24 h |
Disrupt mitochondrial membrane potential. Activated NADPH-oxidase pathway and caused endothelial dysfunction. | [ |
| In-vitro | 1, 2, 3 µM | 24 h |
Decreased expression of FGF-2 protein. | [ |
| In-vitro | 0, 10, 100, 1000 nM | 48 h |
Increased APP synthesis and amyloid beta accumulation. | [ |
Abbreviations: HgCl2- Mercury (II) chloride, ROS: Reactive oxygen species, NO: Nitric oxide, HUVECs: Human umbilical vein endothelial cells, MeHg: methylmercury, LDH: Lactate dehydrogenase, BBB: Blood–brain barrier, VEGF: Vascular endothelial growth factor, PGI2: Prostacyclin or prostaglandin I2, Cox-2: Cyclooxygenase-2, MAPK: Mitogen-activated protein kinase, BAECs: Bovine aortic endothelial cells, NADPH: Nicotinamide adenine dinucleotide phosphate hydrogen, FGF-2: Fibroblast growth factor, APP: Amyloid precursor protein.
Experimental evidences showing the As role in microvascular endothelial and BBB dysfunctions.
| System | Concentration | Exposure Duration | Toxicity | Ref. |
|---|---|---|---|---|
| Invitro | 5 µM | 24 h |
Impaired NO production. Endothelial Activation and Apoptosis, Oxidative stress. | [ |
| In vitro | 7.5 µM | 4–6 h |
Cytotoxicity and oxidative stress. Increase NF-κB, and decreased HO-1 and VEGF expression. | [ |
| In vitro | 5 and 7.5 µM | 4–6 h |
ER pathway mediated endothelial cytotoxicity. Upregulation of Apoptosis cascade. | [ |
| In vitro | 1, 10, 100, and 1000 | 5–72 h |
Endothelial gap junctions are downregulated. Decreases eNOS protein and NO availability. | [ |
| In vitro | 1–5 µM | 24 h |
Endothelial activation. Increases VEGF expression. | [ |
| Invivo | 0.15 mg 1.5 mg 15 mg arsenic trioxide/L | whole lactation |
The decrease in the mRNA expression levels of TJ proteins (Occludin, Claudin, ZO-1 and ZO-2) and Occludin protein. Induces autophagy by inhibiting PI3K/Akt/mTOR signaling pathway. | [ |
| Invivo | 100 ppm | 60 days |
Induces Oxidative stress, and memory impairment. Induces endothelial dysfunction and dementia. | [ |
| Invivo | 4–5 mg/kg/ | Gestation, lactation and until 4 months of age |
Lower response to NMDA receptor stimulation. Reduction of NOS activity and decreased levels of nitrites. | [ |
| 54 arsenicosis patients | - | - |
Impairment of the NO/cGMP pathway in both males and females. | [ |
Abbreviations: HUVECs: Human umbilical vein endothelial cells, NO: Nitric oxide, NF-κB: Nuclear factor kappa- B, HO-1: Heme oxygenase-1, VEGF: Vascular endothelial growth factor, ER: Endoplasmic reticulum, HAEC: Human aortic endothelial cells, eNOS: Endothelial NOS, mRNA: Messenger ribonucleic acid, TJ proteins: Tight junction proteins, ZO-1: Zonula occludens-1, ZO-2: Zonula occludens-2, PI-3K: Phosphatidylinositol 3-kinase, Akt: protein kinase B, mTOR: Mammalian target of rapamycin, NMDA: N-methyl-D-aspartate receptor, NOS: Nitric-oxide Synthase, cGMP: Cyclic guanosine monophosphate.
Experimental evidences showing role of Cd role on brain oxidative stress, apoptosis and endothelial dysfunctions.
| System | Concentration | ExposureDuration | Toxicity | Ref. |
|---|---|---|---|---|
| Zebrafish | 1 mg/L | 24 h and 96 h |
Altered redox balance in the brain at both gene and protein levels. Increased inflammatory cytokines. | [ |
| Zebrafish embryos | 9 µM | 24 h |
Change in the morphology of glial and neuronal cells. Change in the brain mitochondrial morphology. | [ |
| Mice | 3 mg/L | 20 weeks |
Brain function impairment. Olfactory function and memory impairments. | [ |
| Rats | 3 mg/kg | 28 days |
Oxidative imbalance and DNA damage in the brain. Upregulate dShh signaling pathway. Loss of cerebellum structural integrity and motor function. | [ |
| Rats | 5 mg/kg bodyweight | 21 days |
Increased brain cholinesterase, MAO, Na(+)/K(+)-ATPase activities. | [ |
| Rabbits | CdCl2 | 30 days |
Downregulation of Metallothionein along with antioxidant genes. | [ |
| Rats | 32.5 ppm | 2, 3- and 4-month |
Decreased density of dendritic spines. Increased caspase-3 and 9 immunoreactivity. | [ |
| Juvenile mice | 3.74 mg/kg | 10 days |
Hypotrophy and alteration in microstructure and ultrastructure alterations. | [ |
| Rats | 4 mg/kg bw | Single-dose |
A decrease in endothelial barrier antigen expression. Astrocytic deformation. Blurred white and gray matter cytoplasm. | [ |
Abbreviations: NO: Nitric oxide, DNA: Deoxyribonucleic acid, MAO: Monoamine oxidase, Na⁺/K⁺-ATPase: Sodium–potassium adenosine triphosphatase, CdCl2: Cadmium chloride, ppm: parts per million, shh: sonic hedgehog.
Figure 2Mechanism of cerebral endothelial dysfunction imparted by heavy metal intoxication. Heavy metal can generate reactive oxygen species (ROS)by either direct (Fenton reaction) or indirect pathway (activating NADPH oxidase). Reactive oxygen species bind with the NO and rapidly convert into the peroxynitrite resulting in decreases in the bioavailability of NO in endothelial cells. Reduced NO level activates the Rho-kinase. Elevated ROS activity causes the lipid peroxidation of endothelial cells and thus produces the MDA, which is further toxic to the cell. On the other hand, ROS converts in H2O2 catalyzed by SOD. Finally, the reunion of all these events leads to oxidative insults to the endothelial cell and eventually causes endothelial dysfunction. Abbreviations: ROS: Reactive oxygen species, NADPH oxidase: nicotinamide adenine dinucleotide phosphate oxidase, SOD: Superoxide dismutase, H2O2: Hydrogen peroxide, MDA: Malondialdehyde, NO: Nitric oxide, ONOO: Peroxynitrite, Rho-k: Rho-associated protein kinase.
Figure 3Mechanism of heavy metal imparts endothelial inflammation. ROS generation induced by metal exposure from various pathways, which activates an inflammatory cascade via NF-kB, mediated signaling, which triggers the inflammatory gene transcriptions and augments the expression of the pro-inflammatory cytokines such as (TNF-α, IL-1, IL-6, and IL-12). Further, TNF-activation phosphorylated IkB and induced activation of the NF-kB pathway. Thus aggravates the inflammatory and oxidative cycle leading eventually to endothelial dysfunction and promoting CSVD. Abbreviations: TNF: Tumor Necrosis Factor, IL-1: Interleukin-1, IL-6: Interleukin-6, IL-12: Interleukin-12, ROS: Reactive oxygen species, NADPH oxidase: nicotinamide adenine dinucleotide phosphate oxidase, IkB kinase: Inhibitor of kB, NF-κB: nuclear factor kappa B.
Figure 4Role of matrix metalloproteinases (MMPs) in endothelial dysfunctions. Abbreviations: MT-MMPs: Membrane-type matrix metalloproteinases, TNF: Tumor necrosis factor, IL-1: Interleukin-1, NF-κB: nuclear factor kappa b, AP-1: Activator protein 1, BBB: Blood brain barrier.
Heavy Metal Chelators.
| Compound Name | Abbreviation | Molecular Formula | Structure |
|---|---|---|---|
| Calcium Disodium Ethylenediamine Tetra acetic Acid | CaNa2EDTA | C10H12CaN2Na2O8 |
|
| British Anti-Lewisite or 2,3- Dimercaprol | BAL | C3H8OS2 |
|
| Tetrathiomolybdate | TM | MoS42- |
|
| D-Pencillamine | DPA | C5H11NO2S |
|
| meso-2,3-dimercaptosuccinic acid | DMSA | C4H6O4S2 |
|
| Sodium 2,3 Dimercaptopropane-l-Sulphonate | DMPS | C3H7NaO3S3 |
|
| Monoisoamyldimercaptosuccinic acid | MiADMSA | C9H16O4S2 |
|